These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27160425)

  • 1. The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness.
    Zhang LL; Liu HQ; Yu XH; Zhang Y; Tian JS; Song XR; Han B; Liu AJ
    CNS Neurosci Ther; 2016 Aug; 22(8):715-22. PubMed ID: 27160425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel animal model for motion sickness and its first application in rodents.
    Yu XH; Cai GJ; Liu AJ; Chu ZX; Su DF
    Physiol Behav; 2007 Nov; 92(4):702-7. PubMed ID: 17612582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison between two anti-motion sickness drugs].
    Wang J; Qian JK; Wang BZ; Gao JY; Shi HZ
    Space Med Med Eng (Beijing); 1999 Apr; 12(2):138-40. PubMed ID: 12430546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scopolamine for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2004; (3):CD002851. PubMed ID: 15266468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of anti-motion sickness drugs in the squirrel monkey.
    Cheung BS; Money KE; Kohl RL; Kinter LB
    J Clin Pharmacol; 1992 Feb; 32(2):163-75. PubMed ID: 1613127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of modafinil and d-amphetamine in male Sprague-Dawley rats trained to discriminate d-amphetamine.
    Quisenberry AJ; Prisinzano T; Baker LE
    Pharmacol Biochem Behav; 2013 Sep; 110():208-15. PubMed ID: 23880213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy of ginger with various antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Mims ME
    Clin Res Pr Drug Regul Aff; 1988; 6(2):129-36. PubMed ID: 11538042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Model of motion sickness in white mice experiments].
    Zhabko EP; Lukomskaia NIa
    Aviakosm Ekolog Med; 1997; 31(6):66-8. PubMed ID: 9483286
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of anti-motion sickness drugs on motion sickness in rats.
    Morita M; Takeda N; Kubo T; Yamatodani A; Wada H; Matsunaga T
    ORL J Otorhinolaryngol Relat Spec; 1988; 50(5):330-3. PubMed ID: 3186231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation.
    Wesensten NJ; Killgore WD; Balkin TJ
    J Sleep Res; 2005 Sep; 14(3):255-66. PubMed ID: 16120100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility.
    Uijtdehaage SH; Stern RM; Koch KL
    Aviat Space Environ Med; 1993 Jan; 64(1):1-8. PubMed ID: 8424733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats.
    Rowley HL; Kulkarni RS; Gosden J; Brammer RJ; Hackett D; Heal DJ
    J Psychopharmacol; 2014 Mar; 28(3):254-69. PubMed ID: 24327450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.